Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IDEXX Laboratories, Inc. - Common Stock (NQ: IDXX )

413.62 +0.46 (+0.11%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 159,900
Open 412.35
Bid (Size) 413.00 (1)
Ask (Size) 439.98 (1)
Prev. Close 413.16
Today's Range 409.84 - 414.25
52wk Range 398.50 - 583.39
Shares Outstanding 85,075,932
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX
Synopsys, Inc. Named Outstanding Leader, Nell Triplett of Juniper Networks Awarded Outstanding Executive, and IDEXX Laboratories, Inc. Recognized as Breakthrough Corporate Leader 
From Sustainability Roundtable Inc.
Via GlobeNewswire

Performance

YTD
-24.48%
-24.48%
1 Month
-3.49%
-3.49%
3 Month
-18.32%
-18.32%
6 Month
-15.77%
-15.77%
1 Year
-25.61%
-25.61%

More News

Read More
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025
Via The Motley Fool
Topics Stocks
Exposures US Equities
(IDXX) - Analyzing IDEXX Laboratories's Short Interest
Via Benzinga
A Glimpse Into The Expert Outlook On IDEXX Laboratories Through 5 Analysts
Via Benzinga
Decoding 5 Analyst Evaluations For IDEXX Laboratories
Via Benzinga
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization
From IDEXX Laboratories, Inc.
Via Business Wire
IDEXX Announces CFO Transition
From IDEXX Laboratories, Inc.
Via Business Wire
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
Via The Motley Fool
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback
Via The Motley Fool
Topics Stocks
Exposures US Equities
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
Via Benzinga
What Analysts Are Saying About IDEXX Laboratories Stock
Via Benzinga
CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results
From IDEXX Laboratories, Inc.
Via Business Wire
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
Via Benzinga
IDEXX Laboratories to Release 2024 Third Quarter Financial Results
From IDEXX Laboratories, Inc.
Via Business Wire
$100 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth This Much Today
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $800 Today
Via Benzinga
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years
Via Benzinga
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 15 Years
Via Benzinga
IDEXX Laboratories to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From IDEXX Laboratories, Inc.
Via Business Wire
Animal Health Firm Idexx's Robust Business Model Bolsters Position Despite Slower Growth, Says Analyst
Via Benzinga
IDXX Stock Earnings: IDEXX Laboratories Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
IDEXX Laboratories Announces Second Quarter Results
From IDEXX Laboratories, Inc.
Via Business Wire
IDEXX Laboratories Announces Time Change for 2024 Second Quarter Financial Results Conference Call
From IDEXX Laboratories, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.